Skip to main content

Table 2 Details of surgical intervention and postoperative treatment data including complications and recurrence

From: Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival

 

Gastric carcinoma (n = 31)

Esophageal carcinoma (n = 17)

Total (n = 48)

Type of surgery

 Esophagectomy

1 (3%)

15 (88%)

16 (33%)

 Gastrectomy

30 (97%)

2 (12%)

32 (66%)

 HIPEC

14 (45%)

1 (6%)

15 (31%)

Additional resection

 None

10 (32%)

5 (29%)

15 (31%)

 Peritoneum

16 (51%)

2 (12%)

18 (37%)

 Distant lymph nodes

1 (3%)

3 (18%)

4 (8%)

 Liver

1 (3%)

3 (18%)

4 (8%)

 Adrenal

3 (10%)

0

3 (6%)

 Multivisceral resection

0

4 (24%)

4 (8%)

 Perioperative in-patient stay in days

11 (8–23)

14 (7–94)

12 (7–94)

 Perioperative in intensive care in days

4 (2–11)

5 (3–22)

4 (2–22)

Perioperative complications

 Clavien Dindo

13 (42%)

10 (59%)

23 (48%)

 I/II

9 (29%)

7 (41%)

16 (33%)

 III/IV

3 (10%)

1 (6%)

4 (8%)

 V

1 (3%)

2 (12%)

3 (6%)

Resection margin

 R0

21 (68%)

12 (70%)

33 (69%)

 R1 (primary tumor)

3 (9%)

1 (6%)

4 (8%)

 R2 (non-resected metastases)

7 (22%)

4 (23%)

11 (23%)

Postoperative residual tumor

 Local

3 (10%)

1 (6%)

4 (8%)

 Peritoneal carcinomatosis

3 (10%)

2 (12%)

5 (10%)

 Lymph nodes

1 (3%)

2 (12%)

3 (6%)

 Distant metastasis

3 (10%)

0

3 (6%)

 Recurrence

12 (39%)

7 (41%)

19 (40%)

 Time of recurrence after surgery in months*

5,5 (1–15)

6,5 (1–10)

6 (1–15)

Type of recurrence

 Local

1 (8%)

0

1 (5%)

 Local and distant

2 (17%)

2 (29%)

4 (21%)

 Peritoneal carcinomatosis

4 (33%)

1 (14%)

5 (26%)

 Hepatic metastasis

3 (25%)

3 (43%)

6 (32%)

 Other type of metastasis

1 (8%)

1 (14%)

2 (11%)